Mineralys Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 12, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 12, 2025
MLYS$15.52-1.8%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2024 and 2023
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $114,091 | $49,304 |
| Investments | 84,096 | 187,263 |
| Prepaid and other current assets | 7,164 | 12,536 |
| Total current assets | 205,351 | 249,103 |
| Investments, noncurrent | — | 2,482 |
| Property and equipment, net | 53 | — |
| Other assets | 499 | 51 |
| Total assets | $205,903 | $251,636 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $479 | $601 |
| Accrued liabilities | 14,167 | 9,881 |
| Total current liabilities | 14,646 | 10,482 |
| Commitments and contingencies (Note 4) | ||
| Stockholders’ equity: | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2024 and 2023; 49,821,915 and 41,133,916 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 5 | 4 |
| Additional paid-in capital | 493,770 | 365,858 |
| Accumulated deficit | (302,518) | (124,708) |
| Total stockholders’ equity | 191,257 | 241,154 |
| Total liabilities and stockholders’ equity | $205,903 | $251,636 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.